Biomagnetics Diagnostics Corp. is an advanced medical device and biotechnology company with a revolutionary diagnostics system and test kit testing technology for HIV, Hepatitis, H-Pylori, HPV, Tuberculosis and many other viruses, bacterium’s, toxins and diseases. The company focuses on real-time testing for the actual presence of the virus/ toxin/ disease itself, instead of the antibodies produced by the body’s immune system which may take anywhere from weeks to months to appear.

The company intends to follow the lead of established Western drugmakers and biotechs Merck & Co. (MRK), Wyeth (WYE), Eli Lilly & Co. (LLY), Schering-Plough (SGP), Novartis (NVS), Sanofi-Aventis (SNY), Genentech (DNA), Bristol Meyers Squibb (BMYS) and many others that are ramping up investments in China, India and Singapore. The company is currently working to establish a separate Chinese operating company that it intends to apply for listing on the Shenzhen or Hong Kong stock exchange.

Biomagnetics is also currently

...

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition, including Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as the products losing patent protection have. With most of the big pharma companies already facing patent challenges for their blockbuster products or likely to face them going forward, the companies have been looking toward mergers ...

Recently, Merck (MRK) and Schering-Plough (SGP) received approval from the US Federal Trade Commission (FTC), the Swiss Competition Commission and the Canadian Competition Bureau for their proposed merger. However, the transaction has yet to receive approval from other regulators, including China and Mexico. The deal was approved by the European Union antitrust regulators last week. Shareholders of both the companies have already approved the deal in August. Merck expects to close the proposed merger by year end. The FTC approval has come with the condition that both companies will sell some assets. As a result, Schering-Plough has agreed to sell its rolapitant drug, meant to be used for the treatment for nausea and vomiting in chemotherapy patients to Opko Health Inc. In addition, Merck agreed to sell its interest in Merial Ltd, an animal health joint venture, to its French partner, Sanofi-Aventis ...

Pfizer Inc. (PFE) reported third quarter net income of 51 cents per share, which beat the Zacks Consensus Estimate of 48 cents. The company’s net income was 62 cents per share in the year-ago quarter. Revenues for the quarter decreased 3% to $11.6 billion. Revenues for the quarter were unfavorably impacted by approximately 5% due to foreign exchange, and were favorably impacted by 2% due to an adjustment in the third quarter of 2008 for product returns. U.S. revenues, which accounted for 41% of total revenues in the quarter, came in at $4.8 billion, a decrease of 2% compared with the year-ago quarter. International revenues decreased 4% to $6.8 billion, reflecting 5% operational growth and a 9% unfavorable foreign exchange impact. Sales of Pfizer’s mega-blockbuster anti-cholesterol medicine Lipitor fell 9% globally to $2.85 billion in the third quarter. US sales of the drug fell 12%. ...

Companies featured in this edition of the newsletter: CHIP, ENZ, GERS, IWEB, OMCM, ONEZ, XSNX

Markets hit fresh highs for ‘09 yet again last week, as the first round of earnings helped to assuage investor concerns that operating results would underpin robust gains in equities this year. All told, the Dow gained 130 points to end the week at 9995 after briefly cracking the 10,000 mark, gaining 1.3% on the week and extending its gains to 13.9% on the year. The Nasdaq gained 0.8% on the week to close at 2156, up 36.8% on the year, while the S&P 500 and Russell 2000 gained 1.5% and 0.2% respectively, bringing their YTD totals to 20.4% and 23.4%.

Earnings stole the spotlight last week as things got off to a strong start early with JP Morgan handily beating expectations calling for $0.51 per share, reporting earnings of $0.82 per share. Citigroup

...

Following the recent merger of Pfizer (PFE) and Wyeth, a U.S. court imposed a huge fine on the company’s subsidiary Pharmacia & Upjohn for fraudulent marketing of its painkiller Bextra (valdecoxib). The penalty of $1.195 billion was the largest criminal fine ever imposed in the U.S. In addition, a criminal forfeiture of $105 million was enforced on the company.   In September, Pfizer had agreed to pay an additional $1 billion along with interest to settle civil allegations related to fraudulent promotion of four drugs – Bextra, the anti-psychotic drug Geodon, the antibiotic Zyvox and the anti-epileptic drug Lyrica – as well as claims that the company paid kickbacks to physicians to prescribe these and nine other drugs.   In addition to the huge penalty, Pfizer had to agree to comply with the terms of a new and significantly expanded corporate compliance program. It seeks to ensure that ...

The deal between Pfizer Inc. (PFE) and Wyeth was completed yesterday after the receipt of final regulatory approvals. Wyeth will cease to trade as an independent entity from today. Under the terms of the deal, Wyeth shareholders will receive $33 cash (without interest) and 0.985 Pfizer shares for every Wyeth share.   The cash-and-stock deal, which was valued at $68 billion when it was announced nine months ago, stood at about $66.9 billion based on Wednesday’s closing prices. Pfizer borrowed about $22.5 billion to this transaction. Pfizer expects the combined companies to realize synergies of about $4 billion by 2012. The deal is expected to be accretive to earnings by the second full-year following closing. Roughly one-half of the savings are expected to come from Selling General & Administrative costs with the balance coming from Research and Development. Pfizer intends to incrementally pay down the debt financing and ...

U.S. stocks stayed above the threshold reached yesterday as a late-session buying helped offset weakness in banking and technology shares.  Financials dragged on stocks through the early afternoon even as Goldman Sachs and Citigroup reported better-than-expected profit reports.   However, the final fifteen minutes witnessed much of the activity as higher oil prices sent energy stocks higher and, in turn, helped the broader market.

The Dow Jones industrial average closed above the 10,000 level for the second-successive day, edging up 47 points, or 0.5%.  The S&P 500 index edged up 4 points, or 0.4% and the tech-heavy Nasdaq composite ended the day virtually flat.  The gains in the Dow average were led by Microsoft (NASDAQ:MSFT) whose shares jumped 2.9%.  The Windows 7 is slated for release on October 22.

Among energy stocks, Chevron (NYSE:CVX) and ExxonMobil (NYSE:XOM) shares climbed 1.6% and 1.5%, respectively, as crude prices jumped to their highest

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Thursday October 15, 2009

DrStockPick.com Stock Report!

**************************************************************

Cavitation Technologies, Inc. (CTI) (OTC Bulletin Board: CVAT) has signed Miura Engineering Co., Ltd. Tokyo, Japan (www.miura21.co.jp) as its new agent to serve markets in Japan for CTI’s Nano-Cavitation Process Systems. Miura is a leading Engineering Company specialized in Edible Oil Processing Plants in the Far East.

Home Properties (NYSE: HME) is starting to make the conversion from old, outdated, incandescent light bulbs to energy-efficient, longer lasting compact fluorescent light bulbs (CFLs). The change began in

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday October 14, 2009

DrStockPick.com Stock Report!

PFE, PWRM, CSRH, MRK, CVAT, WFC, AQNM, WMT

**************************************************************

PFE, Pfizer Inc.

PFE engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide.

PFE’s s $68 billion purchase of Wyeth will close Thursday after antitrust regulators in the U.S. and Canada cleared the deal.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening

...